Abstract

“Cannabinoid” is the collective term for a group of chemical compounds that either are derived from the  Cannabis plant, are synthetic analogues, or take place endogenously. Though cannabinoids interact largely at the level of the at present recognized cannabinoid receptors, they may well have cross reactivity, such as at opioid receptors. Sufferers with malignant illness represent a cohort inside overall health care that have some of the greatest unmet requirements in spite of the availability of a plethora of guideline-driven illness-modulating remedies and discomfort and symptom management possibilities. Cannabinoid therapies are varied and versatile, and can be supplied as pharmaceuticals (nabilone, dronabinol, and nabiximols), dried botanical material, and edible organic oils infused with  cannabis extracts. Cannabinoid therapy regimens can be inventive, involving combinations of all of the aforementioned modalities. Sufferers with malignant illness, at all points of their illness trajectory, could be candidates for cannabinoid therapies irrespective of whether as monotherapies or as adjuvants. The most studied and established roles for cannabinoid therapies contain discomfort, chemotherapy-induced nausea and vomiting, and anorexia. Additionally, provided their breadth of activity, cannabinoids could be utilised to concurrently optimize the management of several symptoms, thereby decreasing general polypharmacy. The use of cannabinoid therapies could be successful in enhancing good quality of life and possibly modifying malignancy by virtue of direct effects and in enhancing compliance or adherence with illness-modulating remedies such as chemotherapy and radiation therapy.

Copyright © 2018 Elsevier B.V. All rights reserved.

 

Supply:Pubmed

 

PMID: 28050136 PMCID: PMC5176373 DOI: 10.3747/co.23.3487

Maida V1, Daeninck PJtwo.